Related Experiment Video
Updated: Dec 18, 2025
07:22
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
4.2K
Peptide-Based PROTAC: The Predator of Pathological Proteins
Yan Zi Au1, Tingjian Wang1, Logan H Sigua1
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cell Chemical Biology
|June 20, 2020
Summary
Researchers developed a peptide to degrade alpha-synuclein, a protein linked to Parkinson's disease. This targeted protein degradation occurs through the ubiquitin-proteasome system, offering a novel therapeutic strategy.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alpha-synuclein aggregation is a key pathological hallmark of Parkinson's disease.
- Current therapeutic strategies for Parkinson's disease are limited in effectively clearing aggregated alpha-synuclein.
Purpose of the Study:
- To develop a novel peptide-based strategy for targeted degradation of alpha-synuclein.
- To investigate the degradation pathway utilized by the engineered peptide.
Main Methods:
- Design and synthesis of a modular, three-component peptide.
- Utilizing a cell-permeable peptide to target alpha-synuclein within cells.
- Assessing the degradation of alpha-synuclein via cellular pathways.
Main Results:
- Demonstrated successful peptide-induced degradation of alpha-synuclein.
- The peptide specifically targets and reduces alpha-synuclein levels.
- Degradation was mediated through the ubiquitin-proteasome pathway, not the autophagy-lysosome pathway.
Conclusions:
- Peptide-mediated targeted protein degradation is a viable strategy for addressing alpha-synuclein pathology.
- This approach offers a new therapeutic avenue for Parkinson's disease by leveraging the ubiquitin-proteasome system.
Related Concept Videos
02:18The Proteasome
9.9K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.9K
01:13The Proteasome
1.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.7K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:17The Proteasome Structure
1.4K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.4K
01:19Translocation of Proteins into the Mitochondria
11.6K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
11.6K